Blood Cancer Journal · 2021 · 44 citations · 7 references
MedicineHematologyOncologyChemotherapyHematologic OncologyMedical OncologyChemotherapy In Hematologic MalignanciesHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyChronic Myeloid Leukemia TherapyHematologic Malignancy Management
Despite the excellent overall survival (OS) of chronic myeloid leukemia (CML) patients, a significant proportion will fail currently available tyrosine-kinase inhibitors (TKIs) due to resistance or intolerance 1 , 2 , 3 . Intolerant patients are usually managed successfully with alternative second-generation tyrosine-kinase inhibitors (2GTKIs). However, more than half of the patients will eventually discontinue second-line treatment due to loss of response or toxicity 4 , 5 . Ponatinib is an effective drug in the setting of resistance to 2GTKIs, however with life-threatening side effects and varying responses 6 , 7 , 8 .
7
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke et al. · Nature · 2017 · 596 citations
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 467 citations · Full text
Medicine, Oncology, Pharmacology +9